T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$1.01B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$554M |
| 3 |
Canadian Natural Resources
CNQ
|
+$543M |
| 4 |
Goldman Sachs
GS
|
+$528M |
| 5 |
CAVA Group
CAVA
|
+$522M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PNC Financial Services
PNC
|
+$735M |
| 2 |
Microsoft
MSFT
|
+$612M |
| 3 |
TransUnion
TRU
|
+$601M |
| 4 |
Fortinet
FTNT
|
+$514M |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$475M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.09% |
| 2 | Healthcare | 22.65% |
| 3 | Consumer Discretionary | 12.39% |
| 4 | Financials | 11.97% |
| 5 | Industrials | 11.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Mondelez International
MDLZ
$79.4B
| $350K | ﹤0.01% |
+4,796
| New | +$354K |
|
552
Northrop Grumman
NOC
$82B
| $327K | ﹤0.01% |
+716
| New | +$325K |
|
553
Elevance Health
ELV
$86.6B
| $318K | ﹤0.01% |
+715
| New | +$330K |
|
554
SBA Communications
SBAC
$19.4B
| $316K | ﹤0.01% |
+1,363
| New | +$326K |
|
555
Zoetis
ZTS
$30.4B
| $297K | ﹤0.01% |
+1,720
| New | +$297K |
|
556
Applied Materials
AMAT
$435B
| $296K | ﹤0.01% |
+2,044
| New | +$256K |
|
557
Bank of America
BAC
$453B
| $282K | ﹤0.01% |
+9,797
| New | +$280K |
|
558
McKesson
MCK
$102B
| $274K | ﹤0.01% |
+640
| New | +$246K |
|
559
Morgan Stanley
MS
$342B
| $243K | ﹤0.01% |
+2,840
| New | +$243K |
|
560
CSX Corp
CSX
$92.8B
| $232K | ﹤0.01% |
+6,800
| New | +$215K |
|
561
Cadence Design Systems
CDNS
$89B
| $216K | ﹤0.01% |
+918
| New | +$200K |
|
562
Lockheed Martin
LMT
$140B
| $203K | ﹤0.01% |
+440
| New | +$204K |
|
563
Nike
NKE
$60.1B
| $200K | ﹤0.01% |
+1,804
| New | +$211K |
|
564
Monte Rosa Therapeutics
GLUE
$1.36B
| $147K | ﹤0.01% |
21,364
-1,695,701
| -99% | -$11M |
|
|
CYPH
565
Cypherpunk Technologies Inc
CYPH
$70.9M
| $111K | ﹤0.01% |
35,400
-9,944
| -22% | -$49.9K |
|
|
ADVWW
566
DELISTED
Advantage Solutions Warrant
ADVWW
| $76K | ﹤0.01% |
579,413
| – | – |
|
567
AMC Global Media
AMCX
$485M
| – | – |
-640,403
| Closed | -$11.3M |
|
568
Arvinas
ARVN
$580M
| – | – |
-492,180
| Closed | -$13.4M |
|
569
BlackLine
BL
$1.65B
| – | – |
-1,281,913
| Closed | -$86.1M |
|
|
BRT
570
BRT Apartments
BRT
$268M
| – | – |
-311,281
| Closed | -$6.14M |
|
571
Cheesecake Factory
CAKE
$5.84B
| – | – |
-212,346
| Closed | -$7.44M |
|
572
Clearfield
CLFD
$395M
| – | – |
-255,000
| Closed | -$11.9M |
|
573
Cinemark Holdings
CNK
$4.32B
| – | – |
-2,478,695
| Closed | -$36.7M |
|
574
ConocoPhillips
COP
$153B
| – | – |
-1,833,160
| Closed | -$182M |
|
575
Dynatrace
DT
$14.3B
| – | – |
-96,609
| Closed | -$4.09M |
|
Similar funds
T. Rowe Price Investment Management's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Investment Management held 596 positions worth $147B, up 5.3% from $139B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
T. Rowe Price Investment Management's Q2 2023 filing shows 53 new, 243 increased, 259 reduced and 30 closed positions. Its largest new stake was Biogen: 3,399,070 shares worth $968M. The largest sale was PNC Financial Services, an estimated $735M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Investment Management's largest Q2 2023 buy was Biogen: 3,399,070 shares worth $968M.
- T. Rowe Price Investment Management added most to Alphabet (Google) Class A in Q2 2023, an estimated $554M increase.
- T. Rowe Price Investment Management's biggest Q2 2023 reduction was PNC Financial Services, cutting an estimated $735M.
- T. Rowe Price Investment Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023, selling an estimated $331M.
- T. Rowe Price Investment Management's ten largest holdings make up 17% of its $147B portfolio in Q2 2023.
- T. Rowe Price Investment Management opened 53 new positions and closed 30 in Q2 2023.
- T. Rowe Price Investment Management's portfolio value rose 5.3% quarter-over-quarter to $147B.
Based on T. Rowe Price Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.